Recombinant collagen, preparation method and uses thereof

By performing amino acid mutation and bispecific affinity purification tag design on artificial full-length α1 chain, combined with Pichia pastoris expression system and cation exchange chromatography, the degradation problem of α1 chain in Pichia pastoris expression was solved, and the preparation of artificial full-length α1 chain with high purity and high yield was achieved.

JP2024544016AActive Publication Date: 2024-11-26JIANGSU TRAUTEC MEDICAL TECH CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2024533060
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-03
Filing Date
2022-11-23
Publication Date
2024-11-26
Estimated Expiration
2042-11-23

AI Technical Summary

Technical Problem

In the prior art, when using Pichia pastoris to express artificial full-length α1 chains, there are obvious degradation problems, resulting in low yield, low purity, and a complex purification process is required, making it difficult to obtain high-purity full-length α1 chains.

Method used

By performing amino acid mutation on artificial full-length α1 chains, α1(I)M1 and α1(II)M6 variants were designed, bispecific affinity purification tags were added, and Pichia pastoris expression system was used to improve product purity and yield by combining single-use cation exchange chromatography and freeze-drying.

Benefits of technology

The expression and purification of high-purity and low-degradation artificial full-length α1 chain is achieved, maintaining its biological activity and physical and chemical properties, simplifying the purification process and reducing costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544016000001_ABST
    Figure 2024544016000001_ABST
Patent Text Reader

Abstract

The present invention relates to recombinant collagen, preparation methods and uses thereof, in particular to recombinantly expressed full-length collagen α1 chain, preparation methods and uses thereof, which belong to the technical field of collagen expression. [Solution] The mutant of the α1 chain of human type I collagen (α1(I) chain) (designated as α1(I)M1) and the mutant of the α1 chain of human type II collagen (α1(II) chain) (designated as α1(II)M6) constructed in the present invention, when recombinantly expressed in Pichia pastoris, removes the main degradation product (main degradation band) which is generated in essentially the same proportion as the target product (target band) of the full-length α1 chain, which is generated when the natural full-length α1(I) chain and α1(II) chain are recombinantly expressed, improving the yield of the target product, and has physical and chemical properties and biological activity similar to those of the natural full-length α1(I) chain collagen and α1(II) chain collagen recombinantly expressed in Pichia pastoris, making them worthy of use in the field of biomedical materials.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to recombinant collagen, preparation methods and uses thereof, in particular to recombinantly expressed full-length collagen α1 chain, preparation methods and uses thereof, which belong to the technical field of collagen expression. [Background technology]

[0002] Types I and II collagen are typical fibroblast collagens in humans and are composed of three α-peptide chains, each of which contains three parts: an amino-terminal peptide region, a characteristic (GXY)n triplet repeat region, and a carboxy-terminal peptide region.

[0003] Type I collagen is composed of two α1 chains and one α2 chain, and is the most abundant type of collagen in the human body, found in muscle, skin, arterial walls, and fibrocartilage. Type II collagen is composed of three α1 chains and is found mainly in cartilage tissue, vitreous body, and cornea, accounting for more than 90% of the total collagen in the adult cartilage matrix, and is an essential component for cartilage and bone formation, bone growth, and the maintenance of mature cartilage.

[0004] Collagen, an important natural biological protein, has unique functional characteristics such as good biocompatibility, bioactivity and degradability, and is widely used in many fields such as chemical industry, medicine, food, cosmetics, etc., and is especially suitable for the preparation of various biomedical devices, making it the most ideal source of biomaterials and with wide application potential.

[0005] Commercially available collagen is mainly collagen extract obtained by treating animal tissues with acid, alkali and enzymatic hydrolysis, which is severely decomposed during processing and loses biological activity, and the extracted collagen peptides are of different lengths, heterogeneous properties and unstable quality, which poses safety risks of viral infections such as mad cow disease and foot and mouth disease. At the same time, the amino acid sequences of collagen derived from animals and humans are significantly different, which is a heterogeneous protein that may cause immune rejection and allergic symptoms.

[0006] If recombinant collagen is produced by genetic engineering technology, these defects can be effectively avoided. In the existing recombinant collagen expression methods, the expression systems of mammalian cells, insect cells (baculovirus), transgenic animals and plants, etc., are mainly used at the scientific research level due to their high cost, low yield and long cycle. In large-scale industrial production, human collagen is mainly expressed by prokaryotic (E. coli) expression systems and Pichia pastoris expression systems. In E. coli, there is no post-translational modification of proteins, and large-scale expression is intracellular expression, which requires cell lysis, and the removal of large amounts of impurities such as host proteins and naturally occurring (cell wall components) endotoxins and peptidoglycans requires complex purification. However, for Pichia pastoris, human collagen is an exogenous protein after all, and when expressed, it will occupy more intracellular resources (the dependent methanol metabolic pathway can express up to 30% of the cell soluble protein), and the cells will make corresponding adjustments to the exogenous protein. In a typical situation, recombinant proteins are subject to severe degradation, and the α1 chains of human type I and type II collagen are long peptide chains of over 1000 amino acids, making them susceptible to degradation.

[0007] The α1 chain sequence of mature human collagen types I and II includes three parts: amino telopeptide, triple helix region, and carboxyl telopeptide. The total length of the α1 chain of human collagen type I (hereinafter referred to as α1(I)) is 1057 amino acids (AA, amino acid), and the total length of the α1 chain of human collagen type II (hereinafter referred to as α1(II)) is 1060 AA. There are many studies and patents on the expression of human α1(I) chain using Pichia pastoris, but there are few studies and patents on the expression of human α1(II) chain. Among the existing research results on Pichia pastoris expressing the full-length α1(I) chain and full-length α1(II) chain, most studies expressed only a part of the sequence of the α1(I) chain, not the mature full-length α1(I) chain. Although some published results express full-length α1(I) chain, they all generate a major degradation product during expression that occupies essentially the same proportion as the target product, and in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), it appears as a major degradation band (major degradation product) that occupies essentially the same proportion as the target band (target product) of full-length α1 chain. Such degradation not only reduces the yield of full-length α1 chain produced by expression, but also reduces the protein content of the target band, whose properties are close to those of the full-length α1 chain. To obtain a single full-length α1 chain product with high purity, two-step dual affinity purification is required, but the purification cost increases due to the increased complexity of the purification process. Therefore, keeping the full-length peptide chain intact, reducing degradation, and maintaining the bioactivity of collagen unchanged are important challenges for the production of recombinant collagen using Pichia pastoris. Summary of the Invention [Problem to be solved by the invention]

[0008] The object of the present invention is to overcome some technical problems existing in the prior art and provide a full-length collagen α1 chain recombinantly expressed in Pichia pastoris, a preparation method and its use. The recombinant human type I collagen α1 chain variant (referred to as α1(I)M1) and the recombinant human type II collagen α1 chain variant (referred to as α1(II)M6) in the present invention, compared with the natural full-length α1(I) chain and α1(II) chain, when expressed in Pichia pastoris, remove the main degradation band (main degradation product) that is basically the same as the target band (target product) of the full-length α1 chain, improve the yield of the target product, and have similar physical and chemical properties and biological activity as the natural full-length α1(I) chain collagen, α1(II) chain collagen expressed in Pichia pastoris, and commercially available human collagen, making them worthy of use in the field of biomedical materials. [Means for solving the problem]

[0009] In order to achieve the above objectives of the present invention, the present invention adopts the following technical solutions: The present invention provides a recombinant collagen α1 chain which is α1(I)M1 or α1(II)M6, wherein the above α1(I)M1 is obtained by amino acid mutation of the natural full-length amino acid sequence of the α1 chain of human type I collagen, and the above α1(II)M6 is obtained by amino acid mutation of the natural full-length amino acid sequence of the α1 chain of human type II collagen.

[0010] Preferably, the number of amino acid mutation sites in said α1(I)M1 is four, and the number of amino acid mutation sites in said α1(II)M6 is nine. Preferably, the α1 chain of human type I collagen is as shown in SEQ ID NO:1, and the mutation sites of the amino acids are M at position 106, R at position 109, M at position 190, and R at position 193, all of which are specifically changed to P.

[0011] The α1 chain of human type II collagen is shown in SEQ ID NO:4, and the mutation sites of the above amino acids are V at position 67, M at position 68, M at position 72, M at position 75, R at position 78, M at position 108, R at position 111, M at position 162, and R at position 165, all of which are specifically changed to P.

[0012] Furthermore, the amino acid sequence of said α1(I)M1 is shown in SEQ ID NO:2, and the amino acid sequence of said α1(II)M6 is shown in SEQ ID NO:5.

[0013] In the present invention, even if there is some change in the type of change of the corresponding amino acid at the mutation site of the amino acid sequence, that is, the mutation site is the same but the type of amino acid changed is different, the same technical effect as that of the present patent can be obtained, and the same technical effect as that of the present patent can also be obtained by mutating one or several sites.

[0014] The present invention further provides a nucleotide sequence encoding the α1 chain of said recombinant collagen, wherein said nucleotide sequence of said encoding recombinant collagen α1 chain comprises a nucleotide sequence encoding α1(I)M1 or α1(II)M6.

[0015] Furthermore, the nucleotide sequence encoding the above-mentioned code α1(I)M1 is shown in SEQ ID NO:3, and the nucleotide sequence encoding the code α1(II)M6 is shown in SEQ ID NO:6.

[0016] The present invention further provides a recombinant expression vector comprising a nucleotide sequence encoding the α1 chain of the above-mentioned recombinant collagen.

[0017] The present invention further provides an engineered bacteria constructed with the recombinant expression vector described above, comprising the recombinant expression vector described above or expressing the recombinant collagen α1 chain described above.

[0018] The host bacterium of the above-mentioned engineered fungus is preferably Pichia pastoris, and the above-mentioned engineered fungus has a deposit date of March 11, 2021, a deposit number of CGMCC NO. 21891 or CGMCC NO. 21892, a taxonomic name of Pichia pastoris, and a depository institution of the General Microbiology Center of the China Commission for the Preservation and Management of Microorganisms, located at No. 3, No. 1, Beichen West Road, Chaoyang District, Beijing. Here, the engineered fungus with deposit number CGMCC NO. 21891 expresses the α1 chain of recombinant α1(I)M1 collagen, and the engineered fungus with deposit number CGMCC NO. 21892 expresses the α1 chain of recombinant α1(II)M6 collagen.

[0019] The host fungus of the present invention is not limited to Pichia pastoris, and as long as secretion and expression can be achieved in Pichia pastoris or other types of yeast fungus according to the method of the present invention, theoretically the same technical effects as those of the present invention can be obtained.

[0020] The present invention further provides a use of said recombinant expression vector or said engineered bacteria for expressing said recombinant collagen α1 chain.

[0021] The present invention further provides a method for preparing the above recombinant collagen α1 chain, the preparation method comprising the steps of:

[0022] (1) synthesizing a nucleotide sequence encoding the α1 chain of recombinant collagen; By changing the corresponding amino acids at the amino acid sequence sites of the α1 chain sequence of natural collagen, 4 amino acids were changed in the α1 chain of type I collagen to obtain α1(I)M1, and 9 amino acids were changed in the α1 chain of type II collagen to obtain α1(II)M6. Affinity purification tags were added to the amino and carboxy termini of the sequences, and DNA sequences encoding α1(I)M1 and α1(II)M6 were synthesized to contain bispecific affinity purification tags, which contribute to the detection of immunological antibodies based on the two tag sequences. α1(I)M1 and α1(II)M6 have been purified from the major degradation products, which are essentially equivalent to the target bands (target products) of the full-length α1 chain produced when the full-length α1(I) chain and the full-length α1(II) chain are expressed in Pichia pastoris. Compared to the original natural sequence, α1(I)M1 and α1(II)M6 have amino acid mutations located in the characteristic (GXY)n triple repeat region. However, both amino acids are located at X and Y, and the structural characteristics of the collagen (GXY)n triple repeat amino acid sequence remain unchanged, so they still maintain similar physical and chemical properties and biological activity to the original collagen.

[0023] (2) Constructing a recombinant expression vector The synthesized DNA was ligated into the expression vector pPIC9K to construct two recombinant expression vectors, pPIC9K-COL1A1M1 expressing recombinant α1(I)M1 collagen and pPIC9K-COL2A1M6 expressing recombinant α1(II)M6 collagen, respectively.

[0024] (3) Constructing recombinant engineering strains, inducing expression, and screening the strains. The recombinant expression vector was linearized with Sac I, electrotransformed into Pichia pastoris competent cells, transferred to MD plates for pre-screening, screened by YPD plates containing different concentrations of G418, picked colonies and inoculated into BMGY medium, induced expression in BMMY medium, and screened for high-expressing engineered strains. The above-mentioned screened high-expression engineered bacteria are Pichia pastoris, and the deposit numbers are CGMCC NO. 21891 and CGMCC NO. 21892, respectively.

[0025] (4) Fermentation and cultivation at high density High-expressing engineered bacteria identified by protein expression are fermented and cultured at high density in a fermenter.

[0026] (5) Purifying proteins The fermentation supernatant was purified by primary cation exchange chromatography and freeze-dried to obtain high-purity α1(I)M1 and α1(II)M6 collagens.

[0027] The α1(I)M1 and α1(II)M6 recombinant collagens expressed in Pichia pastoris obtained by the present invention were analyzed by characterization of protein properties and in vitro experiments, and the proteins obtained by the present invention match the structural features of the recombinant collagens, have cell adhesion activity, and are basically identical to commercially available human collagens, but more importantly, the structural features and cell adhesion activity of the two mutant proteins and the collagen before mutation are similar or identical.

[0028] The present invention further provides a composition comprising the α1 chain of recombinant collagen as described above or the α1 chain of collagen prepared by the method as described above.

[0029] The present invention further provides a product comprising the recombinant collagen α1 chain or the collagen α1 chain prepared by the method or the composition, including, but not limited to, medicines, pharmaceutical compositions, medical devices, biomaterials, tissue engineering products, cosmetics, or health care products.

[0030] In addition, the above products include materials that provide cells with space for attachment, support, growth and migration, or act as channels for the transport of nutrients and metabolic products.

[0031] Moreover, the above product is a collagen hydrogel.

[0032] The present invention further provides uses for preparing finished products such as the recombinant collagen α1 chain, nucleotides, recombinant expression vectors, engineered bacteria, compositions, etc., including, but not limited to, uses for pharmaceuticals, medical devices, biomaterials, tissue engineering products, cosmetics, or health care products.

[0033] The present invention further provides a use of the above recombinant collagen α1 chain, nucleotide, recombinant expression vector, engineered bacteria or composition for preparing a product for promoting wound repair or tissue regeneration, further, the above product is a collagen hydrogel. Effect of the Invention

[0034] (1) The collagen α1 chain mutant of the present invention has an extremely small percentage of altered amino acid sites in the original natural sequence (the percentage of mutated amino acids is less than 1%, and the homology of the amino acid sequences before and after the mutation is 99% or more), and while obtaining a completely recombinant α1 chain collagen, the properties of the original protein itself (physical and chemical properties, biological activity) are not changed, and when prepared into related products, they have the same properties and biological activity as recombinant proteins with the natural sequence. α1(I)M1 compared with α1(I), and α1(II)M6 compared with α1(II), have similar physical and chemical properties and biological activity, making them worthy of use in the field of biomedical materials. The present invention has conducted cell adhesion experiments on α1(I)M1, α1(II)M6, α1(I), and α1(II), and found that there is no significant difference in cell adhesion activity between α1(I)M1 and α1(II)M6 compared with α1(II), and that the cell adhesion activity of α1(I)M1 and α1(II)M6 is basically the same as that of commercially available human collagen. Collagen hydrogels were prepared using α1(I)M1, α1(II)M6, α1(I), and α1(II) collagens expressed in Pichia pastoris, and the liquid mechanical properties of the hydrogels were detected. The prepared hydrogels had no significant difference in viscosity, elastic modulus, and swelling degree compared with α1(I)M1 and α1(II)M6 compared with α1(II). The freeze-dried collagen hydrogels were scanned using a scanning electron microscope, and all of them had a porous network structure with pore sizes ranging from 100 to 200 μm, which indicates that they may be used in the field of biomedical materials. When the four collagen hydrogels were co-cultured with NIH / 3T3 cells in vitro and calcein AM was added, live cells that emitted green fluorescence and adhered and grew on the hydrogels were detected, and in addition to MTT detection, blue-purple crystals formed by the adhesion, migration, and growth of live cells within the hydrogels could be observed in all cases.

[0035] (2) In the present invention, the expressed proteins were identified using SDS-PAGE electrophoresis and Western Blot, and the results showed that, for the full-length α1(I) chain and α1(II) chain, when α1(I)M1 and α1(II)M6 were expressed in Pichia pastoris, the main degradation band (main degradation product) which was essentially the same as the target band (target product) of the full-length α1 chain was removed, and the yield of the target product was improved. Then, a high-density fermentation experiment was carried out in a fermenter, and the fermentation product was detected by SDS-PAGE electrophoresis. It was found that α1(I)M1 and α1(II)M6 could maintain the integrity of the target band even under high-density fermentation conditions, and the main degradation band was still not produced, while the recombinant human α1(I) and α1(II) produced by fermentation under the same high-density fermentation conditions produced obvious main degradation bands.

[0036] Furthermore, the recombinant collagen of the present invention can be purified from the fermentation supernatant by a single step of cation exchange chromatography, and then freeze-dried to obtain a freeze-dried sponge of high-purity α1(I)M1 and α1(II)M6 collagen. In SDS-PAGE electrophoresis detection, there is no major degradation band, and only a single band, which is the target product, is detected, so that a high-purity target product can be obtained and the purification cost can be reduced.

[0037] For α1(I) and α1(II), a single step of cation exchange chromatography yields only purified proteins that contain a mixture of the target band (target product, full-length α1 chain) and the main degradation band (main degradation product), so a second affinity chromatography step is required to obtain high-purity α1(I) and α1(II) collagen. [Brief description of the drawings]

[0038] [Figure 1] FIG. 1 is a diagram showing the differences between the amino acid sequences of α1(I)M1 and α1(I), where the differences are indicated by the grey background and bold amino acids. [Diagram 2]FIG. 2 is a diagram showing the differences between the amino acid sequences of α1(II)M6 and α1(II). The differences are indicated by the gray background and bold amino acids. [Diagram 3] FIG. 3 shows the pattern of the pPIC9K-COL1A1M1 vector. [Figure 4] FIG. 4 shows the pattern of the pPIC9K-COL2A1M6 vector. [Diagram 5] FIG. 5 shows SDS-PAGE images of the supernatants obtained after 24 hours of induced expression of α1(I)M1 and α1(II)M6 collagen. [Figure 6] Figure 6 shows WB micrographs of the supernatants from induced expression of α1(I)M1 and α1(II)M6 collagen for 24 hours. The left side of the figure shows a WB micrograph of the anti-6×His Tag antibody, and the right side shows a WB micrograph of the anti-Strep-Tag II antibody. [Figure 7] FIG. 7 shows the mass spectrometry results of the target band and the main degradation bands detected by α1(I) and α1(II) collagen SDS-PAGE. [Figure 8] FIG. 8 shows the mass spectrometry results of the target bands detected by α1(I)M1 and α1(II)M6 collagen SDS-PAGE. [Figure 9] FIG. 9 shows SDS-PAGE of supernatants from 48 hours of induced fermentation of α1(I)M1, α1(II)M6, α1(I), and α1(II) collagen. [Figure 10] FIG. 10 shows SDS-PAGE of purified lyophilized sponges of α1(I)M1, α1(II)M6, α1(I), and α1(II). [Figure 11] FIG. 11 is an analysis diagram of the Fourier transform infrared spectra (FT-IR) of α1(I) and α1(II) collagen. [Figure 12] FIG. 12 is an analysis diagram of the Fourier transform infrared spectra (FT-IR) of α1(I)M1 and α1(II)M6 collagen. [Figure 13] FIG. 13 shows detection of cell adhesion activity of α1(I)M1, α1(II)M6, α1(I), and α1(II) collagens. [Figure 14] Figure 14 shows scanning electron micrographs of the surfaces of freeze-dried α1(I) and α1(I)M1 collagen hydrogels (the top two images are α1(I) collagen hydrogels, and the bottom two images are α1(I)M1 collagen hydrogels). [Figure 15] Figure 15 shows scanning electron microscopy images of the surfaces of freeze-dried α1(II) and α1(II)M6 collagen hydrogels (the top two images are α1(II) collagen hydrogels, and the bottom two images are α1(II)M6 collagen hydrogels). [Figure 16] Figure 16 shows the results of cell adhesion and growth of NIH / 3T3 cells on α1(I) and α1(I)M1 collagen hydrogels. The top three images in the figure show, from left to right, NIH / 3T3 cells that have been adhered and grown on α1(I) collagen hydrogel (photographed with a bright-field microscope), NIH / 3T3 cells that have been adhered and grown on α1(I) collagen hydrogel (calcein AM staining, the bright areas are green fluorescent cells, photographed with a fluorescent microscope), and blue-purple crystals formed in NIH / 3T3 cells grown on α1(I) collagen hydrogel (MTT staining, the black areas are crystals, photographed with a bright-field microscope). The three images below, from left to right, show NIH / 3T3 cells adhered and grown on α1(I)M1 collagen hydrogel (bright-field microscope), NIH / 3T3 cells adhered and grown on α1(I)M1 collagen hydrogel (calcein AM staining, bright areas are green fluorescent cells, photographed with a fluorescence microscope), and NIH / 3T3 cells grown on α1(I)M1 collagen hydrogel forming blue-purple crystals (MTT staining, dark areas are crystals, photographed with a bright-field microscope). [Figure 17]Figure 17 shows the results of cell adhesion and growth of NIH / 3T3 cells on α1(II) and α1(II)M6 collagen hydrogels. The top three images in the figure show, from left to right, NIH / 3T3 cells adhered and grown on α1(II) collagen hydrogel (photographed with a bright-field microscope), NIH / 3T3 cells adhered and grown on α1(II) collagen hydrogel (calcein AM staining, the bright areas are green fluorescent cells, photographed with a fluorescent microscope), and blue-purple crystals formed by NIH / 3T3 cells grown on α1(II) collagen hydrogel (MTT staining, the black areas are crystals, photographed with a bright-field microscope). The three images below, from left to right, show NIH / 3T3 cells adhered and grown on α1(II)M6 collagen hydrogel (bright-field microscope), NIH / 3T3 cells adhered and grown on α1(II)M6 collagen hydrogel (calcein AM staining, bright areas are green fluorescent cells, photographed with a fluorescence microscope), and NIH / 3T3 cells grown on α1(II)M6 collagen hydrogel forming blue-purple crystals (MTT staining, dark areas are crystals, photographed with a bright-field microscope). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0039] In order to enable those skilled in the art to better understand the technical solutions of the present invention, the preferred embodiments of the present invention are described in detail below, but the following embodiments are not intended to limit the scope of the present invention. In the examples of the present invention, conventional molecular biology experimental methods are used without any special explanation, and the processes such as PCR, enzyme digestion, ligation, codon optimization, etc. included in the examples can all be understood and easily performed by those skilled in the art based on the product specifications or basic knowledge in the field, so they will not be described in detail.

[0040] Example 1. Design and synthesis of amino acid sequences The amino acid sequence of the α1 chain of human type I collagen (referred to as α1(I)) was determined by reference to the 162-1218 portion (PRO_0000005720) of the Uniprot database P02452-1 (https: / / www.uniprot.org / uniprot / P02452) sequence, and is the amino acid sequence of the α1 chain of mature human type I collagen, which does not include portions that are processed and lost in the α1(I) precursor protein, such as the signal peptide, C-terminal propeptide, and N-terminal propeptide, and the sequence is shown in SEQ ID NO:1.

[0041] SEQ ID NO:1:

[0042] As a result of long-term experimental research, a mutant of the α1 chain of recombinant human type I collagen, designated α1(I)M1, was obtained. Compared to α1(I), α1(I)M1 has four amino acids changed in the amino acid sequence, and these four amino acids are mutated to proline (Pro, abbreviated as P), and M at position 106, R at position 109, M at position 190, and R at position 193 of the amino acid sequence shown in SEQ ID NO:1 are changed to P, and the remaining amino acid sequence remains unchanged. The homology between α1(I)M1 and α1(I) is 99.6%.

[0043] The total length of the altered amino acid sequence (α1(I)M1) is 1057 AA and the sequence is shown in SEQ ID NO:2.

[0044] SEQ ID NO:2:

[0045] Differences between the α1(I)M1 and α1(I) amino acid sequences are indicated in FIG. 1 by the grey background and bold amino acids.

[0046] The DNA sequence of the gene encoding α1(1)M1 (designated COL1A1M1) shown in SEQ ID NO:2 is shown in SEQ ID NO:3.

[0047] SEQ ID NO:3:

[0048] The amino acid sequence of the α1 chain of human type II collagen (referred to as α1(II)) was determined by referring to the 182-1241 portion (PRO_0000005730) of the Uniprot database P02458 (https: / / www.uniprot.org / uniprot / P02458) sequence. This is the amino acid sequence of the α1 chain of mature human type II collagen, and does not include portions that are processed and lost in the α1(II) precursor protein, such as the signal peptide, C-terminal propeptide, and N-terminal propeptide, and this sequence is shown in SEQ ID NO:4.

[0049] SEQ ID NO:4:

[0050] As a result of long-term experimental research, a mutant of the α1 chain of recombinant human type II collagen, designated α1(II)M6, was obtained. Compared to α1(II), α1(II)M6 has 9 amino acids changed in the amino acid sequence, and these 9 amino acids are mutated to proline (Pro, abbreviated as P), and V at position 67, M at position 68, M at position 72, M at position 75, R at position 78, M at position 108, R at position 111, M at position 162, and R at position 165 of the amino acid sequence shown in SEQ ID NO:4 are changed to P, and the remaining amino acid sequence remains unchanged. The homology between α1(II)M6 and α1(II) is 99.2%.

[0051] The total length of the altered sequence (α1(II)M6) is 1060 AA and the sequence is shown in SEQ ID NO:5.

[0052] SEQ ID NO:5:

[0053] Differences between the α1(II)M6 and α1(II) amino acid sequences are shown in FIG. 2 with a grey background and bold amino acids.

[0054] The DNA sequence of the gene encoding α1(II)M6 (designated COL2A1M6) shown in SEQ ID NO:5 is shown in SEQ ID NO:6.

[0055] SEQ ID NO:6:

[0056] The DNA sequence encoding α1(I)M1 was appended to both ends with a DNA sequence encoding a Strep-Tag II tag at the amino terminus and a DNA sequence encoding a 6xHis Tag tag at the carboxy terminus, and the final expression of α1(I)M1 resulted in a tag-containing protein having a total of 1071 amino acids, as shown in SEQ ID NO:7.

[0057] SEQ ID NO:7:

[0058] After optimized design, the DNA sequence of the gene (designated as COL1A1M1) encoding the amino acid sequence of SEQ ID NO:7 (α1(I)M1) is shown in SEQ ID NO:8.

[0059] SEQ ID NO:8:

[0060] The DNA sequence encoding α1(II)M6 was appended to both ends with a DNA sequence encoding a Strep-Tag II tag at the amino terminus and a DNA sequence encoding a 6xHis Tag tag at the carboxy terminus, and the final expression of α1(II)M6 resulted in a tagged protein with a total of 1076 amino acids, the sequence of which is shown in SEQ ID NO:9.

[0061] SEQ ID NO:9:

[0062] After optimized design, the DNA sequence of the gene (designated as COL2A1M6) encoding the SEQ ID NO:9 (α1(II)M6) amino acid sequence is shown in SEQ ID NO:10. SEQ ID NO:10:

[0063] The synthesis of DNA sequences was commissioned to Nanjingjinsirui Science & Technology Biology Corp., which synthesized the DNA fragments of two genes, SEQ ID NO:8 and SEQ ID NO:10.

[0064] Example 2. Construction of recombinant expression vector and selection of bacterial species (1) Construction of recombinant expression vector The synthesized gene fragments SEQ ID NO:8 and SEQ ID NO:10 were recombined into pPIC9K empty vector (purchased from Thermo Fisher Scientific, Inc.) to precisely insert the target fragment into the reading frame of the secretion vector containing the secretion signal α-factor, obtaining two recombinant expression vector plasmids, pPIC9K-COL2A1M6 expressing α1(II)M6 and pPIC9K-COL1A1M1 expressing α1(I)M1.

[0065] The pPIC9K-COL2A1M6 and pPIC9K-COL1A1M1 plasmids were transformed into competent E. coli DH5α (purchased from Sangon Biotech (Shanghai) Co., Ltd.), and the positive clones were screened on LB resistance plates containing ampicillin, and the recombinant plasmids were extracted and sequenced by identification (completed by Sangon Biotech (Shanghai) Co., Ltd.) and verified accurately. The plasmid patterns of pPIC9K-COL1A1M1 and pPIC9K-COL2A1M6 are shown in Figure 3 and Figure 4, respectively.

[0066] (2) Bacteria selection 10 μg of the above recombinant expression vector plasmid was linearized by enzymatic digestion with SacI (purchased from Dalian TaKaRa Co., Ltd., China; specific procedures were performed according to the kit's instructions) at 37°C overnight, and the linearized plasmid was recovered using a PCR product purification kit (purchased from Seiko Biotechnology (Shanghai) Co., Ltd.) and the volume was adjusted to approximately 10 μL.

[0067] The linearized plasmid was electrically transformed into competent cells of the host species Pichia pastoris SMD1168 (purchased from Thermo Fisher Scientific), and 100 μL to 200 μL of the electrically transformed bacterial solution was coated onto one MD plate, left at room temperature for 10 minutes, and then inverted cultured at 30°C for 2 to 5 days until a single colony (positive transformant) appeared.

[0068] Add 2 mL of sterile double distilled water to the surface of the MD plate and spread the His on the plate surface using a sterile triangular spreader. + The transformants were gently scraped off and transferred to a 50 mL centrifuge tube. The bacterial suspension was diluted with sterile double distilled water and diluted to 10 5 The cells were coated on a YPD plate containing 0.5 mg / mL G418 and inverted cultured at 30°C for 3-4 days until single colonies appeared. The colonies were picked from the YPD plate into a sterile 96-well plate (200 μL YPD / well), mixed evenly, and cultured at 30°C for 48 hours, the bacterial liquid in the well was mixed well, and 10 μL was inoculated into one new sterile 96-well plate, cultured at 30°C for 24 hours, and then this operation was repeated again. After 24 hours, 1 μL was taken from the third 96-well plate and inoculated onto a YPD plate containing 1.0 mg / mL and 4 mg / mL G418, respectively, and cultured at 30°C for 96-120 hours. If the Pichia pastoris transformant can grow on a plate containing high concentration (4 mg / mL) G418, the transformant contains multiple copies of the target gene, which means that multiple recombinant fragments have entered the yeast and been integrated into the yeast chromosome by the same recombination. This stage of screening yielded high copy, high expression recombinant yeast engineered strains.

[0069] Two engineered fungus samples, including pPIC9K-COL1A1M1 and pPIC9K-COL2A1M6, were constructed and deposited in the General Microbiology Center of the China Commission of Microbial Species Preservation and Management.

[0070] The engineered fungus expressing recombinant α1(I)M1 collagen containing the recombinant expression vector pPIC9K-COL1A1M1 has been deposited in the General Microbiology Center of the China Commission for the Preservation and Management of Microbial Species of China, with the deposit number CGMCC NO.21891, the address is No.3, No.1, Beichen West Road, Chaoyang District, Beijing, the date of deposit is March 11, 2021, and the taxonomic name is Pichia pastoris.

[0071] The engineered fungus expressing recombinant α1(II)M6 collagen containing the recombinant expression vector pPIC9K-COL2A1M6 has been deposited in the General Microbiology Center of the China Commission for the Preservation and Management of Microbial Species, with the deposit number CGMCC NO. 21892. The address is No. 3, No. 1, Beichen West Road, Chaoyang District, Beijing, the date of deposit was March 11, 2021, and the taxonomic name is Pichia pastoris.

[0072] Example 3. Inducible expression and identification of recombinant collagen The recombinant engineered strains of α1(I)M1 and α1(II)M6 obtained in Example 2 were respectively taken, and the engineered strain of Pichia pastoris expressing full-length type I collagen α1 chain protein and the engineered strain of Pichia pastoris expressing full-length type II collagen α1 chain protein in the existing patent were used as controls. The two control engineered strains were both existing research results of the inventor's team. The expressed full-length collagen α1 chain was similarly tagged with Strep-Tag II at the amino terminus of the peptide chain, and 6×His Tag at the carboxy terminus, and the rest was identified as Yeast Recombinant Human Type I Collagen α1 Chain Protein, Synthesis Method and Use Thereof. The engineered strain of Pichia pastoris expressing full-length α1(I) chain in the patent was deposited in the General Microbiology Center of the China Commission of Microbial Species Preservation and Management, with the deposit number being CGMCC. NO.17150) and application number 201911088025.0 (name is derived from the patent for the preparation of recombinant human type II collagen single chain by Pichia pastoris, the engineered strain of Pichia pastoris expressing full-length α1(II) chain in the patent has been deposited in the General Microbiology Center of China Commission for the Preservation and Management of Microbial Species of China, the deposit number is CGMCC NO.17149). The four engineered strains were placed in a 100mL Erlenmeyer flask containing 10mL BMGY medium and cultured at 28-30℃, 220rpm until the OD600 reached 2-6 (16-18 days). After centrifugation at 1500-3000g for 5 min at room temperature, the cells were collected, resuspended in BMMY medium until the OD600 reached about 2, and placed on a shaker at 28-30°C and 220 rpm for continued growth for 3 days, with 100% methanol added to the medium every 24 hours until the final concentration of methanol in the medium was 1.0%. After induction by adding methanol for more than 16 hours, a sample of the cell suspension was taken in a 1 mL sampling volume, placed in a 1.5 mL EP tube, and centrifuged at 12000g for 5 min at 4°C, and the expression supernatant was collected and the sample was stored at -80°C for detection for later use.

[0073] The expression supernatant was added with 5x loading buffer (250mM Tris-HCl, pH 6.8, 10% SDS, 0.5% bromophenol blue, 50% glycerol, 5% β-mercaptoethanol), heated in a 100°C metal bath for 10 minutes, and subjected to SDS-PAGE detection. The expressed target protein has a Srtep-Tag II tag at the amino terminus and a 6xHis Tag tag at the carboxy terminus, so anti-Srtep-Tag II and anti-6xHis Tag antibodies (purchased from Nanjing Jinsirui Biotechnology Co., Ltd.) were used for Western Blot detection (specific operations are described in the specification).

[0074] SDS-PAGE of the expression supernatant is shown in Figure 5 below. α1(I)M1, α1(II)M6, α1(I), and α1(II) could all be efficiently secreted into the extracellular expression supernatant by 24-hour induced expression. α1(I) and α1(II) showed a clear major degradation band (<116 kDa) at the expected target band (>116 kDa), while α1(I)M1 and α1(II)M6 of the present invention only had the expected target band (>116 kDa).

[0075] The results were calculated using Image Lab software (Bio-Rad Gel Doc XR+ imager) and are as follows: (1) The apparent molecular weight of the α1(I)M1 target band (116.3 kDa) was essentially the same as that of the α1(I) target band (116.4 kDa), the apparent molecular weight of the α1(II)M6 target band (118.2 kDa) was essentially the same as that of the α1(II) target band (118.1 kDa), and the apparent molecular weights were significantly higher than those of the main degradation bands of α1(I) (104.5 kDa) and α1(II) (106.9 kDa). (2) The ratio of the target band to the main degradation band in the α1(I) electrophoresis results was 51.5%:48.3%, and the ratio of the target band to the main degradation band in the α1(II) electrophoresis results was 52.1%:47.8%, and the proportion of the main degradation product was basically the same as that of the target product.

[0076] As can be seen from the ECL chemiluminescence color development results in Figure 6 (a fully automated chemiluminescence image analysis system, Tanon 5200, synthesizes the molecular mass standard of protein into the image), the Srtep-TagII tag can be detected at the amino terminus and the 6xHis Tag tag can be detected at the carboxy terminus. The target bands have the same apparent molecular weight as those in SDS-PAGE. The two recombinant collagens, α1(I)M1 and α1(II)M6, can be efficiently secreted and expressed with their full-length sequences. The expression of the target bands was as expected. The target band sequences of the two collagens, α1(I) and α1(II), were full-length, but the main degradation bands lacked the amino terminus sequence, and only the carboxy terminus 6xHis Tag tag was detected.

[0077] The target bands of α1(I)M1 and α1(II)M6 in SDS-PAGE, the target bands of α1(I) and α1(II) in SDS-PAGE and the main decomposition bands were excised and enzymatically digested with trypsin, and the trypsin decomposition peptide fragments of the recombinant collagen (completed by Suzhou Putai Bio-Technology Co., Ltd.) were detected by Nano-HPLC-MS / MS mass spectrometry, and the detected peptide fragments were sequenced (Uniprot database). The data comparison results and the comparison overlay of the identified peptide fragments and the native sequence (the areas with gray background are the areas in the band where the peptide fragments identified by mass spectrometry are completely identical to the native sequence) are shown in Figures 7 and 8, and the results are as follows: (1) The peptide fragments detected after enzymatic digestion in α1(I)M1, the target band of α1(I), and the main degradation band of α1(I) all belong to the sequence of the type I collagen α1 chain. (2) The peptide fragments detected after enzymatic digestion in the target bands of α1(II)M6 and α1(II) and the main degradation band of α1(II) all belong to the sequence of the human type II collagen α1 chain.

[0078] These results indicate that α1(I)M1 and α1(II)M6 can be expressed in the same way as α1(I) and α1(II), and belong to the recombinant collagens of human type I collagen α1 chain and human type II collagen α1 chain, respectively. However, when α1(I) and α1(II) are expressed, degradation occurs, and the main degradation bands belong to the corresponding types of collagen.

[0079] Example 4. Fermentation and purification at high density (1) High-density fermentation of genetically engineered bacteria Recombinant α1(I)M1 and α1(II)M6 collagens were expressed and produced on a large scale, and fermentation broth containing the recombinant collagens was obtained. Seed medium YPG (containing 10 g / L yeast powder, 20 g / L yeast peptone, and 10 g / L anhydrous glycerol), fermentation medium (containing 190.4 g / L NH4H2PO4, 10.06 g / L KH2PO4, 1.18 g / L CaSO4·2H2O, 18.2 g / L K2SO4, 14.9 g / L MgSO4·7H2O, and 40 g / L glycerol), feed medium (containing 50% W / V glycerol and adding 12 mL PTM1 trace elements per liter), induction medium (containing 100% methanol and adding 12 mL PTM1 trace elements per liter), PTM1 was filtered and sterilized with a 0.22 μm filter membrane and stored at 4°C. After the fermentation medium was sterilized at high temperature and cooled to room temperature, PTM1 was added and the pH was adjusted to 5.0 with ammonia water.

[0080] The batch culture conditions and inducible expression conditions of the engineered strain are as follows: The fed-batch culture method was adopted, and the culture temperature was 30°C. The engineering fungus was inoculated into a 1L shake bottle of seed-containing medium YPG and cultured at 220 rpm and 30℃ for 18-20 hours until OD600=2-10. A 5L fermenter (Guangzhou Baoxing Biological Technology Co., Ltd.) was used to add 2L of fermentation medium (containing 2% glycerol) and sterilize it separately. Before inoculation, the rotation speed was adjusted to 300 rpm, the aeration rate to 4L / min, and the temperature to 30℃, and the pH was adjusted to 4.5 with an alkaline solution prepared with concentrated ammonia water. Then, 0.9mL of PTM1 was inoculated, and the prepared 200mL seed solution was inoculated into the tank (inoculation by flame ring), and the dissolved oxygen electrode was clicked to the hundredth calibration, and fermentation was started after the hundredth calibration. When the growth dissolved oxygen first dropped to 30%, the growth dissolved oxygen was kept at 30% by the dissolved oxygen / rotational speed cascade function. When glycerol was consumed and the dissolved oxygen rebounded, and the dissolved oxygen exceeded 70% (OD600 value of about 20), the dissolved oxygen cascade speed control was released, the stirring was adjusted to 650 rpm, and glycerol was supplied at 30%. The supply volume was 80 mL. Glycerol supplementation was stopped, and after the dissolved oxygen rebounded to 70% or more, the pH was set to 4, the temperature was set to 29°C, and induction culture was performed using a mixed carbon source of methanol and glycerol (methanol: 50% glycerol = 7:3). 5 mL of the above mixed carbon source was manually added, and after the dissolved oxygen rebounded to 70% or more, the supply rate was set to 8 mL / h, increased to 10 mL / h after 1 hour, and increased to 20 mL / h again after 1 hour. If the dissolved oxygen value is less than 30%, stop the supply and reconnect the supply when the dissolved oxygen rebounds and the dissolved oxygen returns to 30%. Induce for 40-60 hours, and if the protein concentration does not increase significantly or decreases as measured by UV, put it in the tank. The formula for protein quantification by UV is C(mg / mL)=0.144*(A215-A225), where A215<1.5.At the same time, an engineered strain of Pichia pastoris expressing the full-length α1(I) chain (the deposit number of the strain at the General Microbiology Center of the China Microbial Species Collection and Management Committee is CGMCC NO. 17150) and an engineered strain of Pichia pastoris expressing the full-length α1(II) chain (the deposit number of the strain at the General Microbiology Center of the China Microbial Species Collection and Management Committee is CGMCC NO. 17149) were obtained and fermented at high density.

[0081] The results are shown in Table 1. After 48 hours of induction, α1(I) was compared with α1(I)M1, and α1(II)M6 was compared with α1(II) in three indicators, namely bacterial concentration (OD600), bacterial wet weight, and UV quantification of the concentration of expressed protein in the fermentation liquid, and there was no significant difference. However, the results of SDS-PAGE electrophoresis detection of collected fermentation supernatants are shown in Figure 9. Under high-density fermentation conditions, the main degradation bands of α1(I) and α1(II) are very obvious, which is the same as the induced expression by shaking bottles. The most main products of α1(I)M1 and α1(II)M6 are still their target bands, and no major degradation bands have appeared, which means that the removal effect of the main degradation bands (main degradation products) of α1(I)M1 and α1(II)M6 is effectively maintained even under high-density fermentation conditions.

[0082] [Table 1]

[0083] (2) Collagen purification Buffer A: 20 mM KH2PO4, pH is 4.0. Buffer B: 20 ​​mM KH2PO4, 0.5 M NaCl, pH 4.0. The fermentation broth was collected, and the cells and fermentation supernatant were centrifuged at 2000g, 30min, 4℃. The cation exchange medium (chromatographic packing material was UniGel-80sp, manufactured by SUZHOU NANOMICRO TECHNOLOGY CO., LTD., loaded into a GCC-50-400 chromatography column, manufactured by Lisure Science (Suzhou) Co., Ltd., using a GE AKTA Pure Protein Separation, Chromatography, and Purification System) was balanced with buffer A until the A215 absorbance value and conductivity value did not change, and then the flow rate was set to 40us / cm and loaded, with a sample volume of 0.5L / time. When the UV A215 absorbance value increased, sample collection was started. After loading is completed, stop taking samples, balance the cation chromatography medium with buffer A, and when the absorbance value of A215 decreases, the ultraviolet light and conductivity do not change until they drop to a minimum value. The eluate is collected, the components are detected and quantified individually, and then dialysis (the dialysis solution is ultrapure water) is performed, followed by concentration and freeze-drying to collect the freeze-dried collagen sponge. The purified freeze-dried sponge is dissolved in ultrapure water and subjected to SDS-PAGE electrophoresis, which is shown in Figure 10. After α1(I)M1 and α1(II)M6 are purified by one-step ion exchange, most of the impurity proteins, small degradation bands, etc. are removed, and a single target protein with high purity is obtained (calculated using Image Lab software, the purity of α1(I)M1 is 90.1%, and the purity of α1(II)M6 is 88.3%).After the same purification process was carried out on α1(I) and α1(II), the main degradation band still appeared and could not be removed. The main degradation products are similar in size and properties to the target products, making it difficult to separate them by one-step purification. According to the contents of the patents with application numbers 201911135958.0 and 201911088025.0, the single target full-length α1(I) chain and full-length α1(II) chain products can only be achieved by using Ni-NTA and Strep-Tactin affinity chromatography media for dual affinity purification, due to the nature of the full-length α1(I) chain and full-length α1(II) chain having Srtep-TagII tag at the amino terminus and 6×His tag at the carboxy terminus. In SDS-PAGE, the main degradation products of the main degradation band were discarded, which wasted the biosynthetic resources of the bacterial cells, increased the purification steps, and reduced the yield of the target product.

[0084] Example 5. Detection of recombinant collagen (1) Fourier transform infrared spectrum (FT-IR) analysis In the test, a small amount of purified freeze-dried samples of α1(I)M1, α1(II)M6, α1(I), and α1(II) collagen was taken, mixed with potassium bromide (KBr), ground into powder, and compressed into tablets. -1 The range was scanned (Thermo Scientific, Nicolet TM iS TM 10 FT-IR spectrometer), and the method and analysis of the results refer to (Jeong, H.J. Venkatesan and S. Kim, Isolation and characterization of collagen from marine fish (Thunnus obesus). Biotechnology and Bioprocess Engineering, 2013. 18(6): p. 1185-1191.).

[0085] The infrared spectra obtained by scanning the purified protein samples of α1(I)M1, α1(II)M6, α1(I), and α1(II) are shown in Figures 11 and 12. The characteristic absorption mean wavenumbers are amide A (3299 cm -1 degree), Amide B (3081 cm -1 ), amide I (1650cm -1 ), amide II (1530-1550cm -1 ), amide III (1240 cm -1 It was found that the structural characteristics of recombinant collagen, which is about 100% pure, are consistent with those of recombinant collagen, indicating that the amino acid mutations in α1(I)M1 and α1(II)M6 do not affect the properties of collagen itself (references [1]. Chen Jingtao et al., Studies on the infrared spectrum of recombinant collagen and bovine type I collagen. Material Guide, 2008(03): pp. 119-121. [2]. Doyle, BB, EG Bendit and ER Blout, Infrared spectroscopy of collagen and collagen-like polypeptides. Biopolymers, 1975. 14(5): p. 937-957. [3]. Zhou Aimei et al., Separation and purification of recombinant human collagen and its structural characteristics. Food and Fermentation Industry, 2015(03): pp. 46-52).

[0086] (2) Detection of cell adhesion activity of recombinant collagen For the detection method of the cell adhesive activity of recombinant collagen, refer to the literature: Juming Yao, Satoshi Yanagisawa, Tetsuo Asakura. Design, Expression and Characterization of Collagen-Like Proteins Based on the Cell Adhesive and Crosslinking Sequences Derived from Native Collagens, J Biochem. 136, 643-649 (2004). It was entrusted to and completed by the Functional Nanomaterials and Biomedical Testing Laboratory of the School of Pharmacy, Changzhou University.

[0087] The specific implementation method is as follows: normal cultured NIH / 3T3 cells (purchased from the Cell Bank of the Chinese Academy of Sciences, product number is GNM6, and the culture and subculture methods are performed according to the cell specifications). Freeze-dried sponges of recombinant α1(I)M1, α1(II)M6, α1(I), and α1(II) collagen, control human collagen (purchased from Sigma, product number is C7774), and bovine serum albumin (BSA, purchased from Seiko Bio (Shanghai) Co., Ltd.) were taken and dissolved (ultrapure water or 1M HCl solution), and the protein concentration was measured according to the UV protein quantification empirical formula C (mg / mL) = 0.144 × (A215-A225), and diluted to 0.5 mg / mL with PBS (pH 7.4). 100 μL of various protein solutions and blank PBS solution controls were added to a 96-well cell culture plate, left at room temperature for 60 minutes, and 10 well-cultured NIH / 3T3 cells were added to each well. 5 The wells were then incubated at 37°C and 5% CO2 for 60 minutes. The cells in the wells were washed four times with PBS. The absorbance value at OD492nm was detected using an LDH detection kit (Roche, 04744926001) (specific operations were performed according to the specifications).

[0088] The characteristics corresponding to the absorbance at OD492nm can represent the cell adhesion activity of collagen samples, the higher the absorbance at OD492nm, the more cells the protein will adhere to, and the higher the adhesion activity, the faster the cells will adhere to the wall or the extracellular matrix, which contributes to the construction of a better extracellular environment. The results are shown in Figure 13, and the recombinant α1(I)M1, α1(II)M6, α1(I), and α1(II) collagens all have similar cell adhesion activity to commercial natural human collagen, all of which are higher than the control group. Compared with α1(I)M1, and compared with α1(II), α1(II)M6 has basically the same cell adhesion activity, with no significant difference.

[0089] (3) Preparation and detection of recombinant collagen hydrogels Recombinant α1(I)M1, α1(II)M6, α1(I), and α1(II) collagens were dissolved in water for injection at a concentration of 10%, the pH was adjusted to the range of 4-6, and sterilized by filtration through a 0.22 μm sterile filter. 0.1 g of 10% (w / w) sterile N-hydroxysuccinimide (NHS) solution was added per 1 g of collagen dry powder and mixed uniformly, and then 0.13 g of 50% (w / w) sterile 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) solution was added per 1 g of collagen dry powder and allowed to react at room temperature (20-30 °C) for 2-6 hours to produce a hydrogel. The hydrogel was continuously dialyzed for 120 hours against a sterile PBS solution (NaCl 8.5 g / L, Na2HPO4 0.5 g / L, NaH2PO4 0.15 g / L, pH 7.2) at a ratio of gel:PBS dialysis solution = 1:6 (m / m), and the dialysate was completely replaced every 24 hours to remove the residual NHS and EDC. The dialyzed hydrogel was placed in a sterile container and left at room temperature.

[0090] The hydrogel is freeze-dried to remove the water, and the freeze-dried hydrogel is weighed and placed in sterile PBS solution for 24 hours again. After the hydrogel has completely absorbed water and swelled, it is taken out, absorbed with absorbent paper, and weighed. The swelling ratio: Q 膨潤率 =(W 吸水膨潤質量 -W 乾燥ゲル重量 ) / W 乾燥ゲル重量 The elastic modulus of the hydrogel (storage modulus, small amplitude frequency scan, 25 °C, stress 0.5%, 0.1 to 100.0 rad / s), dynamic viscosity (flow peak hold, 25 °C, shear rate 2.0 s) were calculated using a rheometer (Discovery HR-2). -1 ) was detected. The freeze-dried hydrogels were rapidly frozen in liquid nitrogen, broken, and the surfaces of the freeze-dried hydrogels were scanned using a scanning electron microscope (Hitachi TM3030PLUS). The results of the elastic modulus, dynamic viscosity, and swelling ratio are shown in Table 2. The hydrodynamic properties of the hydrogels prepared under the same conditions were basically the same for α1(I)M1 compared to α1(I), and for α1(II)M6 compared to α1(II), and did not change significantly.

[0091] [Table 2]

[0092] As shown in Figures 14 and 15, the hydrogels prepared with α1(I)M1 and α1(II)M6, like the hydrogels prepared with α1(I) and α1(II), have a porous network structure with pore sizes ranging from 100 to 200 μm, good permeability, and a spatial structural basis for retaining large amounts of water. These hydrogels may be used in the field of biomedical materials as spaces for cell adhesion, support, growth and migration, or as channels for transporting nutrients and metabolic products.

[0093] (4) Detection of cells in recombinant collagen hydrogels The sterilely stored hydrogel was placed in a 24-well cell culture plate. Normal cultured NIH / 3T3 cells (purchased from the Cell Bank of the Chinese Academy of Sciences, product number GNM6, culture and subculture methods were performed according to the cell specifications) were taken, washed with PBS, digested with trypsin, added with medium, pipetted uniformly, counted, and then cultured at 10 5 The cells were seeded at 100 cells / well onto a cell culture plate containing hydrogel and co-cultured for 24 to 72 hours to observe the adhesion and proliferation of cells on the hydrogel.

[0094] (1) Take a 24-well plate, prepare 1 mM calcein AM (purchased from Beyotime Biotechnology Inc.) in DMSO, and dilute it to 50 μM calcein working solution with D-PBS. Aspirate the medium in the well, wash multiple times with PBS, add 1 mL of serum-containing DMEM medium, add 100 μL of calcein AM solution (1 / 10 of the medium), incubate for 30 minutes, stain the cells, replace the growth medium, culture for 30 minutes, gently remove the hydrogel, place it in a new culture well, and take a picture with a fluorescent microscope (the maximum excitation light wavelength is 494 nm, and the maximum emission wavelength is 514 nm).

[0095] (2) Take another 24-well plate, add 200 μL of MTT solution (purchased from Biyuntian Institute of Biotechnology), and culture NIH / 3T3 cells for 4 hours. After that, observe the formation of blue-purple crystals on the cells. Discard the medium, wash the hydrogel with PBS, cut the hydrogel lengthwise, place it in a new culture well, and take a photograph under a microscope.

[0096] The experiments in this example were completed by the Functional Nanomaterials and Biomedical Testing Laboratory of the School of Pharmacy, Changzhou University. The results are shown in Figures 16 and 17. When observed under a bright field microscope, the morphology of NIH / 3T3 cells in the hydrogels prepared with α1(I)M1 and α1(II)M6 was normal, similar to that of the hydrogels prepared with α1(I) and α1(II). When the NIH / 3T3 cells attached and grown on the hydrogels were stained with calcein AM, green fluorescence was detected (bright areas in the photographs). The NIH / 3T3 cells grown on the hydrogels were When MTT was added, blue-purple crystals were formed (black parts in the photo). The green fluorescence and blue-purple crystals were only formed by living cells, indicating that NIH / 3T3 cells could adhere, grow, and migrate normally within the hydrogel. The hydrogels prepared with α1(I)M1 and α1(II)M6 have similar biological functions to those prepared with the native sequences of α1(I) and α1(II), and may be applied as novel biomedical devices in fields such as wound repair and tissue regeneration.

Claims

1. The α1 chain of recombinant collagen is α1(I)M1 or α1(II)M6, wherein the α1(I)M1 is obtained by amino acid mutation of the natural full-length amino acid sequence of the α1 chain of human type I collagen, and the α1(II)M6 is obtained by amino acid mutation of the natural full-length amino acid sequence of the α1 chain of human type II collagen, and the sequence of the α1(I)M1 is shown in SEQ ID NO:2, and the sequence of the α1(II)M6 is shown in SEQ ID NO:

5.

2. A nucleotide sequence encoding the α1 chain of the recombinant collagen of claim 1.

3. The nucleotide according to claim 2, characterized in that the nucleotide sequence of the code α1(I)M1 is shown in SEQ ID NO:3 and the nucleotide sequence of the code α1(II)M6 is shown in SEQ ID NO:

6.

4. A recombinant expression vector comprising the nucleotide sequence of claim 2.

5. 5. An engineered fungus which is a Pichia pastoris comprising the recombinant expression vector of claim 4 or expressing the α1 chain of recombinant collagen of claim 1.

6. The engineered fungus according to claim 5, wherein the engineered fungus is deposited in the General Microbiology Center of China Commission of Microbial Species Preservation and Management, with the deposit number CGMCC No. 21891 or CGMCC No. 21892, wherein the engineered fungus with the deposit number CGMCC No. 21891 expresses the α1 chain of recombinant α1(I)M1 collagen, and the engineered fungus with the deposit number CGMCC No. 21892 expresses the α1 chain of recombinant α1(II)M6 collagen.

7. Use of the recombinant expression vector according to claim 4 or the engineered fungus according to any one of claims 5-6 for preparing the recombinant collagen α1 chain.

8. (1) synthesizing a nucleotide sequence encoding the α1 chain of the recombinant collagen according to claim 1; (2) constructing a recombinant expression vector; (3) constructing an engineered strain, inducing expression, and screening the strain to obtain a high-expressing engineered strain; (4) Fermenting and culturing the highly expressing engineered bacteria obtained by screening at high density; and (5) The fermentation supernatant is purified and then freeze-dried to obtain the α1 chain of recombinant collagen.

2. The method for preparing the recombinant collagen α1 chain according to claim 1, comprising:

9. The preparation method according to claim 8, characterized in that said high expression engineered fungus is Pichia pastoris, which is deposited in General Microbiology Center of China Commission of Microbial Species Preservation and Management, with deposit number CGMCC No. 21891 or CGMCC No. 21892.

10. A composition comprising the α1 chain of recombinant collagen according to claim 1 or the α1 chain of recombinant collagen prepared by the method according to any one of claims 8 to 9.

11. A pharmaceutical product, a medical device, a biomaterial, a tissue engineering product or a cosmetic, characterized in that it comprises the recombinant collagen alpha 1 chain according to claim 1, the recombinant collagen alpha 1 chain prepared by the method according to any one of claims 8 to 9, or the composition according to claim 10.

12. 12. The product according to claim 11, characterized in that it is a material that provides cells with space for adhesion, support, growth and migration, or is a channel for transporting nutrients and metabolic products.

13. 13. The product of claim 12, wherein the product is a collagen hydrogel.

14. Use of the recombinant collagen alpha 1 chain according to claim 1, the nucleotide according to any one of claims 2-3, the recombinant expression vector according to claim 4, the engineered fungus according to any one of claims 5-6, the recombinant collagen alpha 1 chain prepared by the method according to any one of claims 8-9, or the composition according to claim 10 for the preparation of a finished product which is a pharmaceutical product, a medical device, a biomaterial, a tissue engineered product, or a cosmetic product.

15. Use of the recombinant collagen alpha 1 chain according to claim 1, the nucleotide according to any one of claims 2-3, the recombinant expression vector according to claim 4, the engineered fungus according to any one of claims 5-6, the recombinant collagen alpha 1 chain prepared by the method according to any one of claims 8-9, or the composition according to claim 10 for the preparation of a product for promoting wound repair or tissue regeneration.

16. 15. The use according to claim 14, characterized in that the finished product is a collagen hydrogel.

17. The use according to claim 15, characterized in that the product is a collagen hydrogel.

Citation Information

Patent Citations

  • Recombinant human collagen and its coding gene and preparation method thereof

    CN106554410A

  • Yeast recombined human-source I-type collagen alpha1 chain protein, synthesis method and application thereof

    CN109988234A

  • Recombinant human collagen and application thereof

    CN110003324A

  • Method for producing recombinant human type II collagen single chain by Pichia pastoris

    CN110029111A

  • Method for producing recombinant humanized II-type collagen single chain by using pichia pastoris

    CN110747198A